The company states: "Acorda Therapeutics announced that the Nasdaq Hearings Panel has granted the Company’s extension request until June 20, 2023 to regain compliance with the Nasdaq’s minimum $1 bid price per share requirement. If at any time before June 20, 2023 the bid price of Acorda’s stock closes at or above $1 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules. In the event that the Company cannot regain compliance organically during the extension period, the Company has committed to effecting a reverse stock split, which was authorized by shareholders in November 2022."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACOR:
